
Wednesday, November 23, 2022 10:15:07 AM
https://www.lawow.org/karp-vs-acadia-pharmaceuticals-inc-2021-11-22/
2 people died because Acadia illegally hired a convicted felon as a pharma sales, rep that sold them fentanyl. Unlimited damages and liabilities. Why would Acadia hire a felon? Why does Stephen Davis have his shirt unbuttoned down so far during conference calls?
Uh Oh! what about this lawsuit??? Hmmm...????
NEW ORLEANS, Nov. 11, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD).
On July 20, 2020, the Company announced that the FDA had accepted for filing its supplemental new drug application ("sNDA") for its drug candidate, pimavanserin, for the treatment of dementia-related psychosis ("DRP"). Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drug's efficacy. Then, on April 5, 2021, the Company disclosed that the FDA had rejected the sNDA, citing a lack of statistical significance regarding some of the subgroups of dementia and inadequate numbers of patients with some less common dementia subtypes.
Liked By
Spread the love. Be the first to like this post!
Recent ACAD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/19/2023 10:31:39 PM
- Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications • Business Wire • 09/19/2023 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/15/2023 05:06:45 PM
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences • Business Wire • 08/30/2023 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2023 11:31:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2023 03:15:59 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/14/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2023 08:23:56 PM
- Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview • Business Wire • 08/02/2023 08:05:00 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/01/2023 11:30:00 PM
- Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer • Business Wire • 07/24/2023 08:05:00 PM
- Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023 • Business Wire • 07/19/2023 08:04:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2023 10:00:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2023 08:01:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/14/2023 03:33:21 PM
- Friday’s Wall Street Highlights: JPMorgan Chase, Coinbase, UPS, Theseus Pharmaceuticals, and more • IH Market News • 07/14/2023 11:51:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/14/2023 12:27:47 AM
- Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome • Business Wire • 07/13/2023 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/13/2023 02:42:59 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/26/2023 09:00:00 PM
- Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome • Business Wire • 06/13/2023 08:05:00 PM
- Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome • Business Wire • 06/08/2023 03:10:00 PM
- Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference • Business Wire • 06/01/2023 01:04:00 PM
- Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview • Business Wire • 05/08/2023 08:05:00 PM
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/05/2023 08:04:00 PM
FEATURED Trio Petroleum Corp Provides Update on Testing of the HV-1 Discovery Well • Sep 21, 2023 9:38 AM
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation • GNPX • Sep 20, 2023 8:45 AM
Caduceus Provides Update on Its Plans for The Second Half of The Fiscal Year • CSOC • Sep 20, 2023 8:26 AM
RESILIENT ENERGY INC. (RENI) PURSUING ACQUISITION TARGETS • RENI • Sep 19, 2023 10:30 AM
Aether Global Innovations Corp. Signs Strategic Partnership MOU with STA, a cutting-edge, innovative and bespoke technology solutions provider • AETHF • Sep 19, 2023 9:11 AM
From Instagram to High Times: Unpacking the Power of Vast User Networks • META • Sep 19, 2023 8:45 AM